NCI disclosure of walk-out by Data and Safety Monitoring Board of the National Lung Screening Trial may be harmful, improper, experts say.
NCI Cancer Bulletin publicized board’s resignation over liability concerns.
NCI reassigns project officer John Gohagan.
Also in this 8-page issue: NCI, FDA open Web site for adverse event reporting.
Kansas Cancer Institute gets $15 million pledge, is renamed, and hires a new director in effort to win NCI center grant.
Funding opportunities listed.
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- How will FDA regulate psychedelics?
- Cancer hospitals brace for impact, as CMS moves to slash 340B payments by 33%
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- Vermont researchers discover transmissible cancer in catfish—first ever in a freshwater animal
- The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the way
Knudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long”









